<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Taba">
 <table frame="hsides" rules="groups">
  <tbody>
   <tr>
    <td align="left">The outbreak of coronavirus disease 2019 (COVID-19) affects the management of several cutaneous immune-mediated chronic diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, not only for those who are already receiving treatment but also for those who are about to start a new treatment to control their disease.</td>
   </tr>
   <tr>
    <td align="left">The host’s dysregulated and excessive innate immune response is an important contributor to the disease process and tissue damage in severe cases of severe acute respiratory syndrome coronavirus 2 infection.</td>
   </tr>
   <tr>
    <td align="left">Some selective immunosuppressants or immunomodulatory drugs might be useful in controlling the “cytokine storm” associated with a poor outcome of COVID-19.</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
